Live event and webcast today at 10am ET
Saint Herblain (France), October 10, 2024 – Valneva SE (Nasdaq: VALN, Euronext Paris: VLA), a specialty vaccines company, today held an investor day in New York City and announced plans for the next 12 years. Discuss the company’s key value drivers. – From 18 months onwards. Valneva’s Chief Executive Officer Thomas Ringelbach, Chief Financial Officer Peter Buehler, and other members of the company’s senior leadership team are excited about the company’s significant opportunity for Lyme disease vaccine candidate, led by partner Pfizer, and growing Highlights Valneva’s commercial vaccine business and ongoing value opportunities. Creation from our promising R&D pipeline.
The presentation begins today at 10 a.m. ET (4 p.m. CET) and can be viewed in the presentation section of Valneva’s website. The event will also be webcast live and archived on the event page in the Investor section of Valneva’s website. The conference will be conducted in a hybrid format: in-person and webcast. Click here to register. Two Q&A sessions will be held during and immediately following the formal presentation, providing an opportunity for virtual attendees to participate.
Valneva emphasizes that:
The company’s vaccine candidate for Lyme disease, VLA15, is now fully enrolled in the primary vaccination series, having completed a pivotal Phase 3 trial led by Pfizer. The company’s commercial portfolio of revenue-generating traveler vaccines includes , including the continued launch of IXCHIQ® against chikungunya virus. The company’s clinical and preclinical R&D pipeline includes ongoing clinical development of IXCHIQ® (Phase 4 and other studies), SV4 against Salmonella rubrum in Phase 2, and VLA1601 against Zika virus in Phase 1. Contains. Valneva will also discuss further R&D pipeline developments and current selections. lead target. A brief financial overview focusing on 2024 and medium-term guidance will also be included.
“This is a pivotal time for Valneva as we enter our third and final tick season before the Phase 3 clinical trial for our Lyme disease vaccine VLA15 concludes next year,” said Thomas Ringelbach, CEO of Valneva. ” he said. We are also supported by expected revenue growth from our existing portfolio of travel vaccines in the coming years, including the global launch and rollout of IXCHIQ®, once approved and commercialized by our partner Pfizer. We are confident that we can achieve sustainable profitability from 2027. We will continue to invest in the development of differentiated vaccines in the high areas of unmet medicine, in line with our vision of contributing to a world where no one dies or suffers from vaccine-preventable diseases. I am committed to that. ”
About Valneva SE
We are a vaccine specialist company that develops, manufactures, and commercializes vaccines to prevent infectious diseases in response to unmet medical needs. We take a highly specialized and targeted approach, applying deep expertise across multiple vaccine modalities and focusing on delivering first, best or only-in-class vaccine solutions. Masu.
The company has a strong track record of advancing multiple vaccines from early research and development to approval, and currently has three proprietary travel vaccines, including the world’s first and only chikungunya vaccine, as well as certain third-party vaccines. On sale.
Revenues from our growing commercial business will help fuel the continued progress of our vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, in partnership with Pfizer, and the world’s most clinically advanced rubella vaccine candidate, as well as Zika virus and other It also includes vaccine candidates against global public health threats. For more information, please visit www.valneva.com.
Valneva Investor and Media Contacts
Laetitia Bachelot-Fontaine
Vice President of Global Communications and European Investor Relations
M +33 (0)6 4516 7099
laetitia.bachelot-fontaine@valneva.com
Dr. Joshua Drum
Vice President of Global Investor Relations
M +001 917 815 4520
joshua.drumm@valneva.com
Forward-looking statements
This press release contains certain forward-looking statements regarding Valneva’s business, including: Medium-term earnings and cash outlook. the progress, timing, results and completion of research, development and clinical trials for our product candidates; regulatory approval of product candidates and requested label extensions; and reviews of existing products. In addition, even if Valneva’s actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not persist in the future. In some cases, words such as “may”, “should”, “may”, “expect”, “anticipate”, “believe”, “intend”, “estimate”, ” “target”, “target” or similar words. These forward-looking statements are based primarily on Valneva’s current expectations as of the date of this press release and are subject to numerous known and They may be subject to unknown risks, uncertainties and other factors. Any future results, performance or achievements expressed or implied by these forward-looking statements may differ. In particular, Valneva’s expectations are subject to uncertainties and delays associated with vaccine development and manufacturing, unexpected clinical trial results, unanticipated regulatory actions and delays, general competition, currency fluctuations, and the impact of global conditions. may be affected. global and European credit crisis, the ability to obtain or maintain patents or other proprietary intellectual property protection; The success of preclinical studies or early clinical trials may not be indicative of the results of future clinical trials. Given these risks and uncertainties, there can be no assurance that the forward-looking statements contained in this press release will actually materialize. Valneva is providing this information as of the date of this press release and does not intend to publicly update or update any forward-looking statements, whether as a result of new information, future events or otherwise. We have no intention or obligation to modify it.
